Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

NCT05166577 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Nasopharyngeal Carcinoma
EBV-Related Gastric Carcinoma
EBV-Related Leiomyosarcoma
EBV Related Carcinoma
EBV-Related Sarcoma

Interventions

DRUG: Nanatinostat
DRUG: Valganciclovir
DRUG: Pembrolizumab

Sponsor

Viracta Therapeutics, Inc.